Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline
- Author:
Kyung Jin MIN
1
;
Sang Hoon KWON
;
Kidong KIM
;
Sunghoon KIM
;
Hyun Jung KIM
;
Seok Ju SEONG
;
Yong Jung SONG
;
Keun Ho LEE
;
Shin Wha LEE
;
Jeong Won LEE
;
Suk Joon CHANG
;
Woong JU
;
Young Tak KIM
;
Jae Kwan LEE
Author Information
- Publication Type:Review
- Keywords: Papillomavirus Vaccines; Practice Guidelines; Female; Male
- MeSH: Appointments and Schedules; Female; Humans; Korea; Male; Papillomavirus Vaccines; Vaccination
- From:Journal of Gynecologic Oncology 2019;30(2):e31-
- CountryRepublic of Korea
- Language:English
- Abstract: In 2016, 9-valent human papillomavirus (HPV) vaccine has been newly introduced in Korea, thus the need to develop recommendations for the vaccine has raised. Until we decide to develop a guideline, no further studies on the bi-valent or quadri-valent HPV vaccine have been announced. We searched and reviewed the literatures focused on the efficacy of 9-valent HPV vaccine, the ideal age of 3-dose schedule vaccination, the efficacy of 9-valent HPV vaccine in middle-aged women, the efficacy of the 2-dose schedule vaccination, the safety of 9-valent HPV vaccine, the possibility of additional 9-valent HPV vaccination, and cross-vaccination of 9-valent HPV vaccine. So, Korean Society of Gynecologic Oncology (KSGO) developed a guideline only for 9-valent HPV vaccine.
